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INTRODUCTION
The Gerbich (Ge) blood group consists of antigens that are lo-
cated on glycophorin C, glycophorin D, or both.1 There are six 
known high-prevalence antigens (Ge2, Ge3, Ge4, GEPL, 
GEAT, and GETI) and five low-prevalence antigens (Wb, Lsa, 
Ana, Dha, and GEIS).2 In Melanesians of Papua New Guinea, 
over 50% of the population is Ge-negative, and about 10% is 
reported to have natural anti-Ge.3 In general, however, Ge is a 
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In this study, we report a case of anti-Gerbich (Ge) alloantibody to a high-prevalence Ge antigen in a donor with Fy(a-b-) pheno-
type. The alloantibody was detected in an Emirati boy who was admitted to a Korean tertiary hospital for marrow hematopoietic 
progenitor cell donation. He did not have a history of transfusion. His blood type was A, RhD+, and findings from the antibody 
screening and identification test showed 2+ reactivity in all panel cells except autologous cells. We concluded that it would be 
very difficult to find compatible blood components for the donor and requested further tests from external laboratories. Anti-Ge2 
was identified by additional tests in a foreign reference laboratory, and the Duffy genotype of the donor was FY*02/FY*02N.01 
based on the Korean Rare Blood Program. Although the donor was not a Korean, as the number of foreign patients visiting Korea 
increases annually, there is growing interest in patients with rare blood types in the Korean population. However, there has been 
very little research on rare or high prevalence blood type antigen and antibody in the Korean population. Therefore, additional 
research in Korea is needed on rare blood group antibodies and antigens, including Ge cases. 
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very common blood group system; therefore, it is considered 
to be extremely difficult to find compatible blood compo-
nents for patients with anti-Ge.4 
In this study, we report an Emirati boy who was admitted 
for marrow hematopoietic progenitor cell (HPC) donation to 
his sister. The donor had an irregular antibody identified as 
anti-Ge. In addition, his Duffy phenotype was Fy(a-b-), which 
is extremely rare in the Korean population.5
CASE REPORT
An 8-year-old Emirati boy was admitted to Severance Hospital 
as a marrow HPC donor for his sister in June 2017. He had no 
medical history. On admission, the results of physical examina-
tions and laboratory tests including infectious disease testing 
showed that he was suitable for donation. His blood types were 
A, DCce, Le(a+b-), K-, Jk(a+b+), M+N-S-s+, and Fy(a-b-). The 
donor had no transfusion history. However, antibody screening 
test with ID-Diacell I, II (Bio-Rad, Cressier, Switzerland) and 
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identification test (IDT) with ID-DiaPanel (Bio-Rad) using LISS/
Coombs ID-card (Bio-Rad) based on the column agglutination 
test method showed moderate positivity (2+) in all three screen-
ing cells and 11 identification panel cells with negative reactions 
to autologous red blood cells (RBCs) in anti-human globulin 
phase. An IDT using enzyme (papain)-treated panel cells (ID-
DiaPanel P, Bio-Rad) showed negative reactivities with all panel 
cells. The donor was suspected of harboring antibodies to high-
prevalence antigens, and he showed Fy(a-b-) phenotype, which 
is extremely rare in Korean donors. Therefore, the donor donat-
ed two autologous RBC components before marrow harvest, 
because it could not be ruled out that the donor’s antibody was 
anti-Fy3, which was expected to show incompatibility with al-
most all RBC components from Korean donors. The specimens 
from the donor with informed consent were sent to the Korean 
Rare Blood Program (KRBP) for genotyping of extended blood 
groups. The genotyping was performed using a Lifecodes RBC/
RBC-R typing kit (Immucor, Norcross, GA, USA). The expected 
RBC phenotype based on genotyping is summarized in Table 1. 
These results were consistent with the phenotype tested using 
serologic methods, except the Duffy phenotype. Because the re-
sult of Duffy genotyping was FY*02/FY*02N.01 based on poly-
merase chain reaction–restriction fragment length polymor-
phism analysis, the expected Duffy phenotype of the donor was 
Fy(a-b+). In addition, the specimen of the donor was sent to the 
central laboratory of the Swiss Red Cross in Bern, Switzerland 
for further tests. In that laboratory, the anti-Ge antibody was 
identified. A negative result for Ge2 antigen was also shown us-
ing sera including anti-Ge2. The donor received two autologous 
RBC transfusions after successful marrow HPC collection, and 
the donor was discharged without requirement of allogeneic 
RBC transfusion during his hospitalization. This study was ap-
proved by the Institutional Review Board of Severance Hospital 
(approval number: 4-2018-0437).
DISCUSSION
Both immune-caused and naturally occurring anti-Ge have 
been reported, and a 61-year-old Caucasian male with anti-
Ge alloantibody who had no transfusion history was reported 
previously.6 In our report, the donor did not have any previous 
RBC transfusions; therefore, the anti-Ge2 of the donor could 
be naturally occurring. Anti-Ge2 is not generally considered 
to be clinically significant, although anti-Ge3 causes mild to 
moderate hemolytic transfusion reactions and also causes he-
molytic disease of the fetus and newborn.1 For the case in our 
report, the antibody of the donor could be identified as anti-
Ge2, considering that Ge3 antigen is resistant to papain treat-
ment, whereas Ge2 and Ge4 are sensitive and the reactivity 
with papain-treated panel cells disappeared in this case.1 The 
Ge2 phenotype of the donor was negative. In a previous study, 
more than 90 ABO-identical RBC units were performed cross-
match tests, and none of them were found to be compatible to 
a Saudi Arabian patient with anti-Ge2.4 However, a patient 
with strongly reactive anti-Ge2 received a transfusion of 4 units 
of Ge2-positive RBCs that was well tolerated, and his hemoglo-
bin level increased adequately.7 Therefore, allogeneic RBC 
transfusion to the donor in our case may not be problematic.
In Korea, only one Korean female patient with anti-Ge was 
reported previously.8 The same foreign reference laboratory 
mentioned in our report confirmed the alloantibody. This is 
the second report of an anti-Ge case in Korea; however, the 
case in our report is not of a Korean patient, but of an Emirati 
patient. However, as the number (364189 from 186 countries 
in 2016) of foreign patients visiting Korea increases annually, 
there is growing interest in patients with rare blood types in 
the Korean population.9 Therefore, when a blood transfusion 
is needed in such cases, it can be difficult to prepare when the 
patient has a blood type that is not common in the Korean 
population, or if irregular antibodies to high-prevalence anti-
gens in Koreans are identified in the serum of patients. How-
ever, identification of unknown alloantibodies in both cases 
reported in Korea (previous report8 and our report) was per-
formed in a foreign country, and the result of the anti-Ge in 
our case was known after the donor was discharged. There-
fore, active attempts are needed to establish a national stan-
dard reference laboratory in such areas.
The Duffy genotype of the donor was identified as FY*02/
FY*02N.01. The Fy(a-b-) phenotype occurs in over 63% of Afri-
Table 1. Expected Red Blood Cell Phenotype of an Emirati Marrow Hematopoietic Cell Donor Based on Genotyping from the Korean Rare Blood Program
Phenotype Result Phenotype Result Phenotype Result Phenotype Result
C + hr(B) + Fy(a) - Di(a) -
E - K - Fy(b) + Di(b) +
c + k + M + Do(a) -
e + Kp(a) - N - Do(b) +
C(W) - Kp(b) + S - Jo(a) +
V - Js(a) - s + Co(a) +
hr(S) + Js(b) + U - Co(b) -
VS - Lu(a) - Mi(a) - Yt(a) +
Lu(b) + Hy + Yt(b) -
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can populations. This is caused by homozygosity for the FY*2 
(or FY*B) allele carrying a c.1-67T>C in the GATA-1 promoter 
region, which prevents Fyb expression in RBCs. However, Duffy 
antigens are expressed in non-erythroid tissues, and Africans 
with the Fy(a-b-) phenotype rarely produce anti-Fyb or anti-
Fy3.10 In this case, there was a discrepancy between the results 
of Duffy phenotype and genotype. This may be caused by the 
characteristics of Duffy antigen, zygosity (or dosage effect). 
Red cells from individuals who are heterozygous for the Duffy 
gene may express fewer antigens and, therefore, may be weak-
ly reactive or nonreactive with a weak example of the corre-
sponding antibody.11 Additionally, it was reported that individ-
uals with the same genotype as that in our case could show the 
Fy(a-b-) phenotype.12 In this setting, phenotyping with antise-
rum reagents of different lot number from the same manufac-
turer or those from different manufacturers may be helpful to 
confirm phenotypes. Unfortunately, we did not have access to 
different anti-Fyb antiserum reagents, and therefore, we could 
not further evaluate the Duffy phenotype of the donor in our 
case. According to genetic testing results, the Duffy blood 
group did not need to be considered to identify compatible 
RBC units in our case. However, the genetic testing results 
were also known after the donor was discharged. As men-
tioned above, we suggest that more support is needed for a na-
tional standard reference laboratory.
Fortunately, there were no requirements for allogeneic RBC 
transfusions in the previous report8 and our report. However, it 
seems to be extremely difficult to find compatible RBC com-
ponents in such settings in Korea. In this setting, we have to 
consider autologous RBC transfusion or allogeneic RBC trans-
fusion from family members because it is expected that family 
members are likely to have compatible antigen types. Howev-
er, those transfusion strategies cannot be a solution in all cases. 
Therefore, KRBP, a national rare blood program, was estab-
lished in 2013 to attain an efficient supply of rare blood prod-
ucts. For this purpose, KRBP has investigated the frequency of 
rare blood groups in Koreans and has reported RBC genotyp-
ing for blood groups, including Rh, MNS, Kell, Duffy, Kidd, Lu-
theran, Diego, Cartwright, Scianna, Dombrock, Colton, Land-
steiner-Wiener, Cromer, and Knops, in 419 Korean blood 
donors.13 However, RBC genotyping for the other blood groups 
including Ge cannot be performed by the KRBP. Therefore, 
more national support is needed to ensure that the KRBP has 
the capacity to test for more rare blood groups and irregular 
antibodies to those antigens. In addition, cryopreservation of 
blood represents a possible solution to problems of transfu-
sions in such settings like our report. For this reason, establish-
ment of a national frozen blood storage system for manage-
ment of rare blood supply will be required in Korea.14
In conclusion, anti-Ge2 alloantibody was identified from an 
Emirati boy in a Korean hospital. Fortunately, the donor did 
not require allogeneic RBC transfusions. However, it remains 
extremely difficult to find compatible bloods in such settings 
in Korea. Moreover, there has been very little research on Ge 
blood type antigen and antibody in the Korean population. 
Therefore, additional research in Korea is needed on rare 
blood group antibodies and high prevalence antigens, includ-
ing Ge cases. 
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